Hagar ElGhazawy, Consultant of Clinical Oncology of Breast Cancer Unit, Faculty of Medicine at Ain Shams University, shared a post on LinkedIn:
“What is the optimal Adjuvant Endocrine Therapy (ET) strategy for HR+ BC?
This largest-to-date Network meta-analysis, published in The Lancet, evaluates optimal ET strategies in patients treated in the modern era.
It quantified the expected absolute benefit in terms of improvement in DFS, OS and the number needed to treat (NNT) to avoid 1 relapse.
In addition, it presented pooled safety data, enabling more informed shared decision-making between patients and treating physicians.”
Other articles about Breast Cancer on OncoDaily.